Hologic’s $18.3B Buyout Nears Close After 99.8% Vote, China OKs Acquisition
Hologic’s $18.3 billion buyout by Blackstone and TPG has secured 99.8% shareholder approval and China’s SAMR clearance, offering $76 cash plus up to $3 per share in contingent value rights tied to Breast Health revenue targets. Fiscal Q1 revenue rose 2.5% to $1,047.8 million but missed forecasts and saw margin pressure.
1. Private Takeover Progress
Hologic’s $18.3 billion private takeover by Blackstone and TPG has advanced toward completion after 99.8% shareholder approval at a Feb. 5 special meeting and clearance from China’s State Administration for Market Regulation. The deal terms include $76 per share in cash plus a contingent value right of up to $3 tied to Breast Health revenue goals in fiscal 2026 and 2027.
2. Q1 Financial Performance
In fiscal Q1, Hologic reported revenues of $1,047.8 million, a 2.5% year-over-year increase that nonetheless fell short of analyst expectations. Non-GAAP gross margin declined 150 basis points and operating margin dropped 40 basis points due to higher tariff expenses, while adjusted EPS edged up 1% to $1.04.
3. New FDA HPV Approval
Hologic’s Aptima HPV Assay gained FDA approval for clinician-collected HPV primary screening, expanding its approved cervical cancer screening methods to three approaches. The clearance followed studies involving over 650,000 women and positions the company’s assay among guideline-recommended testing options.